Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CTNM
CTNM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CTNM News
Contineum Therapeutics Reports Q4 Earnings and Public Offering
5d ago
seekingalpha
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Jan 13 2026
Benzinga
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
Dec 12 2025
Newsfilter
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
Dec 12 2025
Businesswire
Contineum Therapeutics Launches $75 Million Public Offering
Dec 11 2025
Newsfilter
Contineum Stock Declines Following Unsuccessful Phase 2 PIPE-307 Trial for Multiple Sclerosis Efficacy
Nov 21 2025
Yahoo Finance
Contineum Therapeutics' Multiple Sclerosis Trial Falls Short, Yet Analyst Believes Other Assets Will Enhance Value
Nov 21 2025
Benzinga
Lululemon Analyst Changes Stance; Check Out Thursday's Top 3 Downgrades
Sep 25 2025
Benzinga
Biogen Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Sep 25 2025
Benzinga
Contineum Therapeutics Announces Encouraging Preliminary Results from PIPE-791 Phase 1b PET Study
Sep 18 2025
NASDAQ.COM
Top Analysts Recommend 3 Stocks to Purchase Now, 8/19/2025
Aug 19 2025
TipRanks
Contineum (CTNM) Q2 R&D Jumps 78%
Aug 06 2025
NASDAQ.COM
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Jun 25 2025
Yahoo Finance
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
Jun 24 2025
Newsfilter
Friday's ETF Movers: XOP, JSMD
Jun 13 2025
NASDAQ.COM
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Apr 28 2025
Newsfilter
Show More News
